Stock Market 26 May 2026 - 27 May 2026

UK & AU Stock Market Today: Live Updates 02.06.2026
···

UK & AU Stock Market Today: Live Updates 02.06.2026

LIVEMarkets rolling coverageStarted: June 2, 2026, 4:00 AM EDTUpdated: June 2, 2026, 4:10 AM EDT Aberdeen Group (LON:ABDN) Shows Strong EPS Growth Amid Mixed Revenue Trends June 2, 2026, 4:10 AM EDT. Aberdeen Group (LON:ABDN) reported a 64% surge in earnings per share (EPS) over the past year, rising from UK£0.13 to UK£0.22, signaling improved profitability. Despite a 2.1% decline in revenue, the company’s EBIT margin increased from 7.4% to 12%, indicating efficient cost management. Insider confidence is notable, with no reported share sales and Non-Executive Director Katie Bickerstaffe purchasing shares worth UK£35,000 at about UK£2.09 each. While Aberdeen’s recent
June 2, 2026
Accuray Stock Nearly Hit 50 Cents — Then the Rally Faded
····

Accuray Stock Nearly Hit 50 Cents — Then the Rally Faded

Accuray Inc. shares fell 0.9% to $0.3712 by late morning in New York after an early surge to $0.4982, with over 14.4 million shares traded. The drop followed the company’s withdrawal of 2026 guidance, citing Middle East shipment delays and a 7% revenue decline last quarter. Analyst downgrades and a May 22 SEC filing showing TCW’s 13.7% stake added pressure. No new corporate news was released Wednesday.
May 27, 2026
Julong falls after Nasdaq trading pause for JLHL
····

Julong falls after Nasdaq trading pause for JLHL

Julong Holding shares fell 9.1% to $17.44 Wednesday after a Nasdaq volatility halt late Tuesday. The stock hit a low of $16.11 and traded lightly, with about 19,344 shares changing hands. No new statements appeared from the company, whose last investor update was a February annual report filing. Julong reported fiscal 2025 revenue of 252 million yuan and net income of 26.2 million yuan.
May 27, 2026
BioNexus Gene Lab Stock Edges Up While Nasdaq Microcap Faces Chemrex Cash Battle
····

BioNexus Gene Lab Stock Edges Up While Nasdaq Microcap Faces Chemrex Cash Battle

BioNexus Gene Lab Corp. rose 1.45% to $2.10 in light Nasdaq trading Wednesday, with under 3,000 shares changing hands. First-quarter revenue dropped to $22,842 from $2.14 million a year ago, mainly due to weaker Chemrex results. The company is seeking to recover $2.94 million from former Chemrex officers over disputed payments. BioNexus warned of “substantial doubt” about its ability to continue as a going concern.
May 27, 2026
First Interstate BancSystem Stock Is Back in Focus After Shelf Filing and Analyst Cut
····

First Interstate BancSystem Stock Is Back in Focus After Shelf Filing and Analyst Cut

First Interstate BancSystem filed an automatic shelf registration Tuesday, allowing it to sell various securities in the future. Shares closed up 1.8% at $36.13 after D.A. Davidson downgraded the stock to Neutral and cut its price target. The filing comes ahead of Wednesday’s shareholder meeting in Billings, Montana. First-quarter net income rose to $60.2 million from $50.2 million a year earlier.
May 27, 2026
This Tiny Medical-Device Stock Is Back Above $11. Its Next FDA Test Is the Whole Trade
····

This Tiny Medical-Device Stock Is Back Above $11. Its Next FDA Test Is the Whole Trade

enVVeno Medical shares traded at $11.25 before Wednesday’s Nasdaq open, valuing the company at $7.4 million. The FDA has cleared enVVeno to begin its pivotal U.S. trial for enVVe, a non-surgical venous valve, with the first stage set to start later this year. The company reported $24.9 million in cash as of March 31, enough to fund operations into Q3 2027.
May 27, 2026
Vestand Stock Gains Premarket as Nasdaq Eyes Delisting Over 50-Cent Price
····

Vestand Stock Gains Premarket as Nasdaq Eyes Delisting Over 50-Cent Price

Vestand Inc. said Nasdaq staff began delisting proceedings after the company missed three financial filings. Vestand requested a hearing, triggering a short automatic stay while it seeks more time. Shares traded near $0.50 premarket Wednesday, up from $0.47 at Tuesday’s close. The company warned there is no guarantee overdue reports will be filed before the hearing or that Nasdaq will grant an extension.
May 27, 2026
First United Moves Premarket as FUNC Jumps
····

First United Moves Premarket as FUNC Jumps

First United shares traded at $38.17, up 2.5% in pre-market Nasdaq activity Wednesday, following a sector lift that saw the SPDR S&P Regional Banking ETF gain 1.3%. The Maryland bank last reported Q1 net income of $6.7 million and a net interest margin of 3.83%. No new company-specific catalyst emerged overnight. Leadership is set to change, with Jason Rush taking over as CEO next year.
May 27, 2026
Casey’s Shares Move Lower Ahead of Results, With Margin Uncertainty in Focus
····

Casey’s Shares Move Lower Ahead of Results, With Margin Uncertainty in Focus

Casey’s General Stores shares fell 1.9% to $809.41 in early trading Tuesday, even as Wells Fargo raised its price target to $910. The drop came as U.S. indexes climbed, with the S&P 500 up 0.6% and the Nasdaq hitting a record. Wells Fargo warned of a possible fourth-quarter EPS miss due to weaker fuel margins. Casey’s will report fiscal Q4 and full-year results after the bell on June 9.
May 27, 2026
Voyager Therapeutics Stock Is Waking Up Before a Make-or-Break Tau Window
····

Voyager Therapeutics Stock Is Waking Up Before a Make-or-Break Tau Window

Voyager Therapeutics shares rose 4 cents to $3.83 in thin premarket trading, valuing the company at $228 million. H.C. Wainwright reiterated a Buy rating and $25 target, citing upcoming milestones including first human dosing for VY1706 and tau PET imaging data for VY7523 in the second half of 2026. Voyager reported $171.7 million in cash at the end of Q1.
May 27, 2026
Zenas BioPharma Stock Slips as a June Catalyst Moves Into View
····

Zenas BioPharma Stock Slips as a June Catalyst Moves Into View

Zenas BioPharma shares fell 1.3% to $18.73 on Tuesday, underperforming the biotech sector ahead of a June 4 presentation of Phase 3 data for its autoimmune drug obexelimab. The trial showed a 56% reduction in IgG4-RD flare risk, below Amgen’s Uplizna, which cut risk by 87%. Zenas plans to seek FDA approval this quarter. Investors remain cautious as the stock trades well below its 52-week high.
May 27, 2026
Plains GP Stock Drops After Holiday Break — What the Move Signals Now
····

Plains GP Stock Drops After Holiday Break — What the Move Signals Now

Plains GP Holdings LP shares fell 1.7% to $25.51 Tuesday, underperforming the broader market as pipeline stocks slipped after the Memorial Day break. No new company news was posted, with the latest update remaining the May 12 sale of its Canadian NGL business for $3.3 billion. Plains All American Pipeline dropped 2.4%. PAGP traded near the top of its 52-week range.
May 26, 2026
Travelzoo Gains as Shares Tick Higher, Traders Look at the Small Cap
····

Travelzoo Gains as Shares Tick Higher, Traders Look at the Small Cap

Travelzoo shares rose 0.8% to $10.11 in late Nasdaq trading Tuesday after U.S. markets reopened from the Memorial Day holiday. The company last reported first-quarter revenue of $24.3 million, up 5% year over year, and earnings per share of 23 cents. Operating income slipped to $3.45 million as sales and marketing costs increased. Trading volume reached about 89,600 shares.
May 26, 2026
NeuroSense trades close to 90 cents as next $1 Nasdaq threshold comes into view
····

NeuroSense trades close to 90 cents as next $1 Nasdaq threshold comes into view

NeuroSense Therapeutics shares rose 5 cents to 87 cents Tuesday, staying below Nasdaq’s $1 minimum bid price. The company faces delisting risk, needing its stock to close above $1 and its market value to reach $35 million for 10 days by Sept. 29, 2026. NeuroSense recently raised $600,000 in a private share sale. Its ALS drug candidate, PrimeC, is set for Phase 3 trials after FDA clearance.
May 26, 2026
1 … 5 6 7 8 9 … 126

Stock Market Today

  • Aberdeen Group (LON:ABDN) Shows Strong EPS Growth Amid Mixed Revenue Trends
    June 2, 2026, 4:10 AM EDT. Aberdeen Group (LON:ABDN) reported a 64% surge in earnings per share (EPS) over the past year, rising from UK£0.13 to UK£0.22, signaling improved profitability. Despite a 2.1% decline in revenue, the company's EBIT margin increased from 7.4% to 12%, indicating efficient cost management. Insider confidence is notable, with no reported share sales and Non-Executive Director Katie Bickerstaffe purchasing shares worth UK£35,000 at about UK£2.09 each. While Aberdeen's recent earnings growth is promising, the revenue dip warrants caution. Investors should weigh these mixed fundamentals carefully when considering Aberdeen for their watchlist.